Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac Safety and PK of Pacritinib in Healthy Subjects
NCT02807207Phase 1Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pacritinib in myelofibrosis (MF) (6 arms), sponsored by CTI BioPharma Corp. Primary endpoint: QT interval calculated using Fridericia correction. Started Oct 2014; status: completed.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02807207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02807207.